Trial Profile

Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Andexanet alfa (Primary) ; Prothrombin complex concentrate (Primary)
Indications Haemorrhage
Focus Adverse reactions
Sponsors AstraZeneca

Most Recent Events

23 Jan 2023 Status changed from recruiting to completed.
10 Nov 2022 Planned End Date changed from 30 Nov 2022 to 19 Dec 2022.
10 Nov 2022 Planned primary completion date changed from 30 Nov 2022 to 19 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com